申请人:PORTOLA PHARMACEUTICALS, INC.
公开号:US20150353495A1
公开(公告)日:2015-12-10
The present invention is directed to compounds of formula I and pharmaceutically acceptable salts, esters, and prodrugs thereof which are inhibitors of JAK kinase. The present invention is also directed to intermediates used in making such compounds, the preparation of such a compound, pharmaceutical compositions containing such a compound, methods of inhibition JAK kinase activity, methods of inhibition the platelet aggregation, and methods to prevent or treat a number of conditions mediated at least in part by JAK kinase activity, such as undesired thrombosis and Non Hodgkin's Lymphoma.
本发明涉及式I化合物及其药学上可接受的盐、酯和前药,它们是JAK激酶抑制剂。本发明还涉及用于制备这种化合物的中间体,制备这种化合物的方法,含有这种化合物的药物组合物,抑制JAK激酶活性的方法,抑制血小板聚集的方法,以及预防或治疗至少部分由JAK激酶活性介导的多种疾病,如不良血栓形成和非霍奇金淋巴瘤的方法。